16:19 , May 23, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of NPY1R bound to tool compound antagonists or its endogenous agonist NPY could guide the design of compounds that antagonize or agonize the receptor for obesity, cancer or bone loss....
22:30 , Mar 16, 2017 |  BC Innovations  |  Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Neuropeptide Y receptor Y2 (NPY2R); peptide tyrosine-tyrosine (PYY) Mouse studies suggest PYY delivered as an...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
07:00 , Apr 14, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Neuropeptide Y receptor Y2 (NPY2R); NPY4R Studies in mice suggest that a lipidated peptide agonist...
08:00 , Feb 7, 2011 |  BioCentury  |  Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc.'s Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be able...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche's Genentech Inc.unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease.1 Nineteen of the 112 candidate cancer genes identified...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

7TM preclinical data

In a mouse model of chemotherapy-induced gastrointestinal disease, TM30339 improved survival and mucositis outcome post X-ray irradiation. The neuropeptide Y (NPY) receptor Y4 agonist is in Phase I/II testing to treat obesity. 7TM Pharma...
07:00 , Aug 31, 2009 |  BioCentury  |  Strategy

Neurogen chronicles

Neurogen chronicles Neurogen Corp. (NASDAQ:NRGN), which is being acquired by Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for $11 million in stock plus conditional payments worth at least $7 million, has had a long history of early clinical failures....
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

PYY: Clinical data

In a double-blind, placebo-controlled, investigator-run, European trial in 16 male volunteers, both 2 mg oral GLP-1 alone and in combination with 1 mg oral PYY(3-36) induced a significant reduction in caloric intake. There was no...